title: Novel alpha- and beta-amino acid inhibitors of influenza virus neuraminidase.
abstract: In an effort to discover novel, noncarbohydrate inhibitors of influenza virus neuraminidase we hypothesized that compounds which contain positively charged amino groups in an appropriate position to interact with the Asp 152 or Tyr 406 side chains might be bound tightly by the enzyme. Testing of 300 alpha- and beta-amino acids led to the discovery of two novel neuraminidase inhibitors, a phenylglycine and a pyrrolidine, which exhibited K(i) values in the 50 microM range versus influenza virus A/N2/Tokyo/3/67 neuraminidase but which exhibited weaker activity against influenza virus B/Memphis/3/89 neuraminidase. Limited optimization of the pyrrolidine series resulted in a compound which was about 24-fold more potent than 2-deoxy-2,3-dehydro-N-acetylneuraminic acid in an anti-influenza cell culture assay using A/N2/Victoria/3/75 virus. X-ray structural studies of A/N9 neuraminidase-inhibitor complexes revealed that both classes of inhibitors induced the Glu 278 side chain to undergo a small conformational change, but these compounds did not show time-dependent inhibition. Crystallography also established that the alpha-amino group of the phenylglycine formed hydrogen bonds to the Asp 152 carboxylate as expected. Likewise, the beta-amino group of the pyrrolidine forms an interaction with the Tyr 406 hydroxyl group and represents the first compound known to make an interaction with this absolutely conserved residue. Phenylglycine and pyrrolidine analogs in which the alpha- or beta-amino groups were replaced with hydroxyl groups were 365- and 2,600-fold weaker inhibitors, respectively. These results underscore the importance of the amino group interactions with the Asp 152 and Tyr 406 side chains and have implications for anti-influenza drug design.
authors.affiliation: Discovery Research, Pharmaceutical Products Division, Abbott Laboratories, Abbott Park, Illinois 60064-6217, USA. warren.kati@abbott.com
authors.forename: W M
authors.initials: WM
authors.lastname: Kati
authors.forename: D
authors.initials: D
authors.lastname: Montgomery
authors.forename: C
authors.initials: C
authors.lastname: Maring
authors.forename: V S
authors.initials: VS
authors.lastname: Stoll
authors.forename: V
authors.initials: V
authors.lastname: Giranda
authors.forename: X
authors.initials: X
authors.lastname: Chen
authors.forename: W G
authors.initials: WG
authors.lastname: Laver
authors.forename: W
authors.initials: W
authors.lastname: Kohlbrenner
authors.forename: D W
authors.initials: DW
authors.lastname: Norbeck
mesh_terms: D000596:Amino Acids / Q000737:chemistry / Q000494:pharmacology*; D000998:Antiviral Agents / Q000737:chemistry / Q000494:pharmacology*; D018360:Crystallography, X-Ray; D005998:Glycine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006900:Hydroxylation; D008958:Models, Molecular; D009439:Neuraminidase / Q000037:antagonists & inhibitors* / Q000737:chemistry; D009975:Orthomyxoviridae / Q000187:drug effects / Q000201:enzymology*; D011487:Protein Conformation; D011759:Pyrrolidines / Q000494:pharmacology
chemical_list: D000596:Amino Acids; D000998:Antiviral Agents; D011759:Pyrrolidines; C027797:phenylglycine chloride; D009439:Neuraminidase; C032519:pyrrolidine; D005998:Glycine